Lanadelumab for Treatment of COVID-19 Disease

Lanadelumab for Treatment of COVID-19 Disease

So far little is very few drugs have demonstrated positive results for treatment of COVID19.

Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

Inclusion Criteria:

• Patient is SARS-COV2 positive (PCR)
• Without oxygen a saturation below 90%
• At least 3L/min oxygen dependent
• Patient is 16 years and older

Exclusion Criteria:

• Has previously participated in this study
• Acute myocardial or cerebral ischemic event at time of enrolment
• Receiving ACE or ARB inhibitor or comparable drugs that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent
• A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal
• Patient is known hypersensitive to full human monoclonal antibodies
• Patient is pregnant or breast feeding